Navigation Links
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Date:4/14/2008

cromet-inc.com" target="_new">(http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual result
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... Dec. 17, 2014  Strategic Health Services, Inc. (SHS), ... today announced a strategic agreement with QualCare, Inc., a leading ... Jersey regional marketplace.  This agreement will further ... and wellness solutions QualCare brings to its clients in ... region. QualCare plans cover more than ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... PHILADELPHIA and LONDON , June 28 ... portfolio of drugs, whilst the proportion of total sales from newer drugs ... Factbook complied by CMR International, a Thomson Reuters business. , ... The new edition of the R&D Factbook ...
... Fla. , June 26 Data ... that linagliptin achieved statistically significant and sustained reductions ... (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose ... dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral ...
Cached Medicine Technology:Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 2Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 2Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 3Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 4Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 5Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 6Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 7Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes 8
(Date:12/17/2014)... participation in music classes may benefit children,s language development, ... the nonprofit Harmony Project, which provides music education and ... two years, children who actively participated in the classes ... and reading, compared to those with lower levels of ... music classes occurred in the same areas of the ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, ... the millions of American women who have migraine: The debilitating ... is no association between migraine and breast cancer risk," said ... Harvard Medical School. "There is no positive association, so there ... effect either." About 18 percent of American women and ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... Reporter , THURSDAY, May 19 (HealthDay News) -- The U.S. ... drug Avandia will no longer be sold at retail pharmacies ... to patients. According to the new rules, which will ... be available to patients who,ve been safely using the ...
... University of Louisville, UCLA and the California Institute of Technology ... a paralyzed male volunteer at Louisville,s Frazier Rehab Institute. It ... potential clinical therapies for paralysis. The study is ... The man, Rob Summers, age 25, was completely ...
... (HealthDay News) -- When people need a self-esteem boost, they ... when they make those expensive purchases, according to new research. ... and then some of the participants were told that they ... while others were told they did well on the test. ...
... (HealthDay News) -- The human ability to stand on two legs ... new study suggests. University of Utah researchers used a punching ... by male boxers and martial arts experts as they hit the ... men struck the bag from a standing position and while on ...
... with defects in mismatch repair--one of the body,s systems ... survival rates than patients without such defects, according to ... Journal of the National Cancer Institute. About ... defects. Some defects are caused by the inherited gene ...
... 2011 The Children,s Health Insurance Program Reauthorization Act ... care quality measures to be identified for voluntary use ... (CHIP), which together cover almost 40 million American children ... the official journal of the American Pediatric Association, noted ...
Cached Medicine News:Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 2Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 2Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 3Health News:Paraplegic man stands, steps with assistance and moves his legs voluntarily 4Health News:Buying Luxury Items on Credit May Be Ego Booster 2Health News:Punches Land Harder When Delivered From Above: Study 2Health News:DNA repair system affects colon cancer recurrence and survival 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 4Health News:Important info about CHIPRA core set of recommended health care quality measures released 5
Unipolar Atrial "J" Lead...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: